Spotlight on the Companies Driving Growth in Microbiology Culture Market
Reshaping Diagnostics: Innovation in the Microbiology Culture Market
The growing need for pharmaceutical development, research, and diagnostic testing has made the microbiology culture market an essential sector of the biotechnology and healthcare sectors. The market includes a broad variety of culture media, tools, and associated services for the cultivation, identification, and research of microorganisms. The market is expected to grow significantly due to biotechnology advancements and an increase in the prevalence of infectious diseases. The future is being shaped by strategic investments and innovations, which makes it a crucial area of focus for stakeholders looking to improve research capabilities and diagnostic accuracy globally.
Market Forecast
The global microbiology culture market size is calculated at US$ 9.38 billion in 2025, grew to US$ 9.93 billion in 2026, and is projected to reach around US$ 16.55 billion by 2035. The market is expanding at a CAGR of 5.85% between 2026 and 2035.
Microbiology Culture Companies Outlook:
- Major Investors: The main firms in the sector that reinvest in R&D, innovation, and strategic acquisitions make up the majority of major investors in the microbiology culture market. Thermo Fisher Scientific Inc., Merck KGaA (which operates as MilliporeSigma in the United States), Becton, Dickinson and Company (BD), bioMérieux SA, and Bio-Rad Laboratories, Inc. are some of these important participants.
Regional Companies Insights:
Asia Pacific
India
- According to the ICMR's Virus Research and Diagnostic Laboratories (VRDL) network, 24,502 (10.7%) of 2,28,856 samples tested positive for pathogens between January and March 2025, and 26,055 (11.5%) of 2,26,095 samples tested positive between April and June 2025. As a result, the infection rate increased by 0.8 percentage points from the previous quarter, indicating that infection trends need to be closely monitored.
- An ICMR study in 2025 found that 1 in 9 persons tested positive for an infectious disease; the infection rate rose by 0.8 percentage points in Q2 2025. The top pathogens detected were Influenza A, Dengue virus, and Hepatitis A, signaling seasonal disease risk.
Europe
- South America is expected to grow significantly in the microbiology culture market during the forecast period. The broader South American market is growing due to infectious disease prevalence and biopharma quality control. International companies, like bioMérieux, acquired local firms in late 2025 to enhance regional microbiological data analytics capabilities.
South America
- South America is expected to grow significantly in the microbiology culture market during the forecast period. The broader South American market is growing due to infectious disease prevalence and biopharma quality control. International companies, like bioMérieux, acquired local firms in late 2025 to enhance regional microbiological data analytics capabilities.
UAE
- In the UAE, the emphasis on high-throughput diagnostics and environmental monitoring elevates the need for high-end, selective media. Premium brands like Merck MilliporeSigma and Thermo Fisher's Oxoid are vital for pharmaceutical sterility testing and cleanroom monitoring, alongside specialized chromogenic media for rapid identification.
- Government funding for healthcare reached $1.36 billion in 2024. The high rate of cardiovascular disease, which accounts for 40% of Emirati mortality, fuels demand for high-complexity IVD tests. The estimated undiagnosed Hepatitis B cases are near two-thirds of an 18,000-patient pool.
Company Landscape
Thermo Fisher Scientific Inc.
Company Overview: A global leader in scientific services, offering a vast array of instruments, consumables, reagents, and services for research, clinical diagnostics, and applied markets. Its microbiology culture portfolio is primarily handled by the Specialty Diagnostics Segment and the Life Sciences Solutions Segment.
Corporate Information (Headquarters, Year Founded, Ownership Type):
- Headquarters: Waltham, Massachusetts, U.S.
- Year Founded: 2006 (through the merger of Thermo Electron and Fisher Scientific, though predecessors date back to 1902).
- Ownership Type: Publicly Traded (NYSE: TMO).
History and Background:
History and Background: Formed through the merger of Thermo Electron Corporation and Fisher Scientific International in 2006. The company's microbiology expertise stems from its acquisition of companies like Remel and Oxoid, providing a foundational and global presence in culture media and microbial identification.
Key Milestones/Timeline:
- 2006: Thermo Electron and Fisher Scientific merge to form Thermo Fisher Scientific.
- 2011: Acquired Dionex Corporation, enhancing chromatography capabilities.
- 2014: Acquired Life Technologies, significantly expanding its life sciences and molecular diagnostics capabilities, including PCR and sequencing.
- 2021: Completed the acquisition of PPD, a leading global clinical research organization (CRO), integrating clinical trial services.
- 2024 (Recent): Continued strategic focus on its single-use technology and cell/gene therapy solutions, which rely on microbial culture quality control.
Business Overview:
Business Overview: Provides a seamless workflow across research, diagnostics, and production. In microbiology, the focus is on end-to-end solutions, from sample collection to identification, susceptibility testing, and food/water safety testing. Annual Revenue (FY 2024 estimate): Approximately $42.86 Billion.
Business Segments/Divisions:
- Life Sciences Solutions: Reagents, instruments, and consumables for cell culture, molecular biology, and proteomics.
- Analytical Instruments: Instruments for laboratory and process control (e.g., mass spectrometry).
- Specialty Diagnostics: Diagnostic test kits, reagents, cultural media (e.g., Oxoid and Remel brands), and instruments for clinical, drug monitoring, and environmental testing.
- Laboratory Products and Biopharma Services: Laboratory equipment, services, and the newly integrated PPD clinical research services.
Geographic Presence:
Geographic Presence: Global presence with major operations in North America, Europe, and Asia-Pacific. North America holds the largest market share in microbiology culture (approx. 38.27% of the global market in 2024), where Thermo Fisher is a dominant player.
Key Offerings:
- Dehydrated Culture Media (DCM) and Prepared Culture Media (PCM) under the Oxoid and Remel brands.
- Automated microbial identification and Antimicrobial Susceptibility Testing (AST) systems (e.g., Sensititre System).
- Molecular detection systems (e.g., SureTect Real-Time PCR).
- Specimen collection and transport systems.
End-Use Industries Served:
End-Use Industries Served: Clinical Diagnostics/Hospitals, Pharmaceutical & Biopharmaceutical Production (largest application segment, accounting for approx. 36.76% of the market in 2024), Food & Beverage Testing, Academic and Research Institutes, and Environmental Testing.
Key Developments and Strategic Initiatives:
Focused on integrating the large acquisition of PPD (2021) to offer end-to-end clinical trial services, which often require extensive microbiology QC.
- Partnerships & Collaborations:
Ongoing collaborations with biopharma companies to supply custom, high-quality media for vaccine and biologic production.
- Product Launches/Innovations:
Launch of new Thermo Scientific Spectra Chromogenic Media for rapid pathogen detection (e.g., MRSA, VRE, ESBL).
Introduction of the Applied Biosystems QuantStudio 5 Food Safety Real-Time PCR System for high-performance microbial testing in food.
- Capacity Expansions/Investments:
Continuous investment in manufacturing capacity for high-demand bioproduction materials, including specialized media for cell and gene therapy, which often requires ultra-pure microbial QC.
Ongoing focus on securing necessary CE-IVD and US FDA 510(k) clearances for diagnostic and clinical microbiology products.
- Distribution Channel Strategy:
Distribution channel strategy: A Direct sales force model combined with an extensive global distributor network. Strong emphasis on its e-commerce platform for lab consumables. Also leverages a Tailored Delivery Solution (TDS) for prepared media to boost lab efficiency and inventory management.
- Technological Capabilities/R&D Focus:
Technological Capabilities/R&D Focus: Focused on Digital Integration of diagnostic instruments, Rapid Molecular Methods (PCR) for quick results, and Advanced Media Formulations (chromogenic, selective, and animal-free media) to fight AMR and improve bioproduction yields.
Core Technologies/Patents:
- Sensititre System: Automated AST system.
- Spectra Chromogenic Media Technology: High-specificity culture media.
- SureTect PCR System: Rapid, accurate molecular detection for food safety.
Research & Development Infrastructure:
Research & Development Infrastructure: Global R&D centers dedicated to life sciences, diagnostics, and bioproduction technologies, ensuring its culture media and systems remain compatible with the latest automation and molecular platforms.
Innovation Focus Areas:
Innovation Focus Areas: Antimicrobial Resistance (AMR) detection, high-throughput automated microbiology systems, development of animal-free and chemically defined media for biopharma, and integration of AI/ML for diagnostic data analysis.
Competitive Positioning:
- Strengths & Differentiators: Unmatched breadth of portfolio (from basic culture media to advanced mass spec), strong brand reputation (Oxoid/Remel), and significant financial resources for continuous M&A and R&D.
- Market presence & ecosystem role: A "one-stop-shop" for scientific needs; leading supplier of basic research consumables and critical diagnostic components. Estimated market share: One of the top two, likely holding a leading share in the total microbiology market.
SWOT Analysis:
- Strengths: Comprehensive product range, leading market share in several segments, strong global distribution.
- Weaknesses: High cost of integration post-M&A, complexity of a massive product portfolio.
- Opportunities: Accelerated demand for high-quality biopharma QC media, growth in Asia-Pacific clinical diagnostics, personalized medicine R&D.
- Threats: Competitive pressure from focused diagnostics companies (e.g., bioMérieux), shift toward non-culture-based molecular diagnostics.
Recent News and Updates:
- Press Releases (2024/2025): Announced Q3 2025 revenue growth, driven by strength in the Specialty Diagnostics segment (including microbiology). Highlighted new solutions in Single-Use Technologies that require stringent microbial testing.
- Industry Recognitions/Awards: Frequently recognized as a top employer in science and for innovation in laboratory instrumentation.
Becton, Dickinson and Company (BD)
Company Overview: A global medical technology company that is a critical provider of medical devices, instrument systems, and reagents. Its microbiology culture business is a core part of its BD Integrated Diagnostic Solutions (IDS) segment.
Corporate Information (Headquarters, Year Founded, Ownership Type):
- Headquarters: Franklin Lakes, New Jersey, U.S.
- Year Founded: 1897.
- Ownership Type: Publicly Traded (NYSE: BDX).
History and Background:
History and Background: Founded over a century ago, BD has a long history in medical devices. It entered the microbiology field in the 1950s, leading to innovations in sterile disposables and diagnostic medicine. The company has maintained a leadership position through its foundational BD Difco and BD BBL brands of culture media.
Key Milestones/Timeline:
- 1897: BD is founded.
- 1955: BD enters the microbiology field.
- 2017: Acquired Bard, significantly expanding its medical device and interventional portfolio.
- 2021: Launched the BD Kiestra™ ID/AST module for automated identification and susceptibility testing in clinical labs.
- April 2025 (Recent): Received US FDA 510(k) clearance for BD Phoenix M50 and BDXpert System on the BD Synapsys Informatics Solution.
Business Overview:
Business Overview: Focuses on improving medical discovery, diagnostics, and the delivery of care. The microbiology culture business is essential for clinical diagnosis and is highly integrated with its automated instrument platforms. Annual Revenue (FY 2024 estimate): Approximately $20.4 billion.
Business Segments/Divisions:
- BD Medical: Medication Management Solutions, Medication Delivery Solutions, and Diabetes Care.
- BD Life Sciences: Includes Integrated Diagnostic Solutions (IDS)—the division responsible for microbiology, molecular diagnostics, and specimen management (e.g., blood culture and culture media, BD BBL and BD Difco).
- BD Interventional: Peripheral Intervention, Surgery, Urology, and Critical Care.
Geographic Presence:
Geographic Presence: Operates in virtually every country globally. Strong foothold in North America and Europe, with increasing investments and market penetration in the Asia-Pacific (APAC) and emerging markets.
Key Offerings:
- BD Difco and BD BBL culture media (Dehydrated and Prepared Media).
- BD BACTEC Blood Culture Systems.
- BD Phoenix Automated Microbiology System for ID/AST.
- BD Kiestra Lab Automation Systems (full-workflow automation for microbiology labs).
- Specimen collection and transport systems.
End-Use Industries Served:
End-Use Industries Served: Hospitals and Diagnostic Laboratories (a dominant end-user segment, processing the largest volume of patient samples), Pharmaceutical and Biotechnology Quality Control, and Academic Research.
Key Developments and Strategic Initiatives:
Focused on divestitures of non-core businesses to streamline and focus on diagnostics, intervention, and smart medical devices.
- Partnerships & Collaborations:
- Strategic partnerships with healthcare systems and GPOs to implement its total lab automation solutions (BD Kiestra).
- Collaboration with public health organizations on global AMR surveillance programs.
- Product Launches/Innovations:
- April 2025: Received US FDA 510(k) clearance for BD Phoenix M50 and BDXpert System for enhanced ID/AST data interpretation.
- Launch of new lines of microbiology products in 2024 to help ease the burden of higher testing volumes in the clinical laboratory.
Capacity Expansions/Investments:
Continued investment in manufacturing for its proprietary culture media brands and automated diagnostic systems.
Regulatory Approvals:
February 2025: BD received FDA 510(k) clearance and CE-IVDR certification for high-throughput enteric bacterial panels on the BD COR™ System.
Distribution Channel Strategy:
Distribution channel strategy: A mature, multi-channel strategy utilizing direct sales for capital equipment (e.g., BD Kiestra, BD Phoenix) and a mix of direct and distributor sales for high-volume consumables like culture media and specimen collection tubes.
Technological Capabilities/R&D Focus:
Technological Capabilities/R&D Focus: Focus on Total Lab Automation to minimize hands-on time, Rapid Diagnostics (faster time-to-result for ID/AST), and Digital Health/Informatics (e.g., BD Synapsys Informatics) to leverage diagnostic data. R&D in new media formulations optimized for automation.
Core Technologies/Patents:
- BD Kiestra System: Modular, automated microbiology laboratory workflow.
- BD Phoenix System: Automated ID/AST technology.
- BD BACTEC System: Automated blood culture and microbial detection.
Research & Development Infrastructure:
Research & Development Infrastructure: Global R&D centers dedicated to infectious disease diagnostics and life science research, focusing heavily on integrating culture media and reagents into automated platforms.
Innovation Focus Areas:
Innovation Focus Areas: Combating AMR through faster and more accurate AST, developing new culture media for emerging pathogens, and integrating diagnostics with informatics to provide actionable clinical insights.
Competitive Positioning:
- Strengths & Differentiators: Strongest position in clinical lab automation (BD Kiestra), highly recognized and trusted culture media brands (BD Difco/BBL), and leadership in blood culture diagnostics (BD BACTEC).
- Market presence & ecosystem role: A dominant player in clinical diagnostics, often providing the full ecosystem from patient sample collection to final diagnostic result. Estimated market share: One of the top two, consistently a major leader in automated clinical microbiology.
SWOT Analysis:
- Strengths: Deep integration in hospital labs through automation, established brands in culture media, and broad geographic reach.
- Weaknesses: Intense competition in molecular diagnostics, dependence on regulatory approvals for new clinical platforms.
- Opportunities: Expansion of automated microbiology in APAC, increasing global focus on sepsis/AMR management, and demand for high-throughput testing.
- Threats: Disruption from non-culture-based diagnostics (e.g., NGS for ID/AST), potential supply chain issues for high-volume consumables.
Recent News and Updates:
- Press Releases (2024/2025): Announced positive Q2 and Q3 2025 results, citing growth in the IDS segment driven by instrument placements and consumable pull-through. Highlighted the launch of new software features for the BD Synapsys system to enhance lab efficiency.
- Industry Recognitions/Awards: Often receives recognition for its work in infection prevention and for its automated diagnostic systems.
Microbiology Culture Market Value Chain Analysis
R&D
The five "I"s of microorganisms, inoculation, incubation, isolation, inspection, and identification, are the focus of research and development (R&D) in microbiology culture. R&D efforts are concentrated on creating new media, automation, and methods for cultivating picky or uncultivated microbes.
Top Companies Include: Thermo Fisher Scientific, Merck KGaA, and BioMérieux
Clinical Trials and Regulatory Approvals
Clinical trials include preclinical research, ethical committee and regulatory (e.g., FDA, CDSCO) approvals, Phase I, II, and III human trials, market authorization/NDA submission, and post-market surveillance.
Key companies Include: Charles River Laboratories, Abbott, Thermo Fisher Scientific, IQVIA, and Parexel, among others.
Distribution to Hospitals, Clinics, and ASCs
In order to guarantee product integrity and quality, microbiology culture medium must be manufactured (by Thermo Fisher Scientific, BD, and Merck), packaged under precise circumstances (temperature control, sterility), and transported via a controlled supply chain to hospitals and clinics.
Recent Developments in the Microbiology Culture Market
- In July 2025, a deal was reached between Bristol Myers Squibb and the company that developed the APAS Independence technology. The technology developed by the business that eliminates manual plate reading in cleanrooms is the main focus of the acquisition. According to Sophie Bullimore, AstraZeneca collaborated with Clever Culture Systems (previously LBT Innovations), a pioneer in automated plate reading, to shift the focus of its A$50 million technology from clinical microbiology to pharmaceutical microbiological testing.
- In March 2025, a Bioengineering Center for Microbial Biofoundry Research is now being planned by the Pune-based NCCS, whose microbial culture library has greatly benefited academics and industry.
Partner with our experts to explore the Microbiology Culture Market at sales@towardshealthcare.com
